Genmab — December 2017
-
“An important randomized study showing that daratumumab is well tolerated in smoldering myeloma and it leads to significantly longer progression free survival"
-
Som Landgren anfører i E L's link, så er der ved at brede sig den opfattelse blandt læger i USA, at smouldering-fasen skal afskaffes. Lav- og mellemrisiko skal henføres under MGUS og ikke behandles. Højrisiko derimod betragtes som aktiv myelomatose og behandles derefter, dvs som alm 1. linje. Bliver det tilfældet i fremtiden, bliver det ikke dara mono, men dara i kombi, der vil blive brugt.
-
Carnegie har sænket kursmålet til 1210 fra 1392
-
Carnegie gentager Hold
-
Carnegies lavere kursmål skyldes ændring af bankens prognose for Darzalex
-
Director of Columbia University Medical Center NY, presented CASTOR on Saturday at ASH, but can't get the name right. Daratutumab, sounds like an egyptian farao
https://www.youtube.com/watch?v=G8oX4WTtLZs -
Carnegie venter Darzalex-salg for 2017 på 1277 mio usd og for 2018 på 2124 mio usd
-
Mcjean, Nordea har ændret deres analyser pga Mifid2. Novod laver kun flash comments til institutionelle investorer. Alle andre kan kun se en oversigt over plusser og minusser ved en aktie
-
Hvad tid er recepttal?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind